X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fresenius Kabi Onco. with Lupin Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs LUPIN LTD - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. LUPIN LTD FRESENIUS KABI ONCO./
LUPIN LTD
 
P/E (TTM) x 22.1 19.8 112.0% View Chart
P/BV x 3.1 2.7 116.2% View Chart
Dividend Yield % 0.0 0.9 -  

Financials

 FRESENIUS KABI ONCO.   LUPIN LTD
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
LUPIN LTD
Mar-17
FRESENIUS KABI ONCO./
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs1761,750 10.1%   
Low Rs791,384 5.7%   
Sales per share (Unadj.) Rs37.7387.4 9.7%  
Earnings per share (Unadj.) Rs5.156.6 9.0%  
Cash flow per share (Unadj.) Rs6.776.8 8.8%  
Dividends per share (Unadj.) Rs07.50 0.0%  
Dividend yield (eoy) %00.5 0.0%  
Book value per share (Unadj.) Rs42.5298.9 14.2%  
Shares outstanding (eoy) m158.23451.58 35.0%   
Bonus/Rights/Conversions -ESOPS-  
Price / Sales ratio x3.44.0 83.5%   
Avg P/E ratio x25.027.7 90.3%  
P/CF ratio (eoy) x18.920.4 92.8%  
Price / Book Value ratio x3.05.2 57.1%  
Dividend payout %013.2 0.0%   
Avg Mkt Cap Rs m20,135707,513 2.8%   
No. of employees `0001.216.8 6.9%   
Total wages/salary Rs m70328,495 2.5%   
Avg. sales/employee Rs Th5,176.210,418.3 49.7%   
Avg. wages/employee Rs Th610.41,697.0 36.0%   
Avg. net profit/employee Rs Th699.61,523.0 45.9%   
INCOME DATA
Net Sales Rs m5,963174,943 3.4%  
Other income Rs m181,065 1.7%   
Total revenues Rs m5,981176,008 3.4%   
Gross profit Rs m1,43044,931 3.2%  
Depreciation Rs m2589,122 2.8%   
Interest Rs m-261,525 -1.7%   
Profit before tax Rs m1,21635,349 3.4%   
Minority Interest Rs m0-72 0.0%   
Prior Period Items Rs m083 0.0%   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m3429,785 3.5%   
Profit after tax Rs m80625,575 3.2%  
Gross profit margin %24.025.7 93.4%  
Effective tax rate %28.127.7 101.6%   
Net profit margin %13.514.6 92.4%  
BALANCE SHEET DATA
Current assets Rs m5,102119,542 4.3%   
Current liabilities Rs m2,38561,206 3.9%   
Net working cap to sales %45.633.3 136.6%  
Current ratio x2.12.0 109.5%  
Inventory Days Days15076 197.4%  
Debtors Days Days11390 126.1%  
Net fixed assets Rs m5,148131,660 3.9%   
Share capital Rs m158903 17.5%   
"Free" reserves Rs m6,556134,073 4.9%   
Net worth Rs m6,732134,976 5.0%   
Long term debt Rs m95256,478 1.7%   
Total assets Rs m10,388266,073 3.9%  
Interest coverage x-45.824.2 -189.4%   
Debt to equity ratio x0.10.4 33.8%  
Sales to assets ratio x0.60.7 87.3%   
Return on assets %7.510.2 73.7%  
Return on equity %12.018.9 63.2%  
Return on capital %14.619.3 75.8%  
Exports to sales %74.50-   
Imports to sales %24.80-   
Exports (fob) Rs m4,441NA-   
Imports (cif) Rs m1,477NA-   
Fx inflow Rs m5,29881,885 6.5%   
Fx outflow Rs m1,77221,506 8.2%   
Net fx Rs m3,52560,378 5.8%   
CASH FLOW
From Operations Rs m1,27441,148 3.1%  
From Investments Rs m-1,204-25,287 4.8%  
From Financial Activity Rs m-1964,332 -4.5%  
Net Cashflow Rs m-12620,193 -0.6%  

Share Holding

Indian Promoters % 0.0 46.6 -  
Foreign collaborators % 81.0 0.2 40,500.0%  
Indian inst/Mut Fund % 0.3 11.3 2.7%  
FIIs % 9.6 31.9 30.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 10.1 90.1%  
Shareholders   42,599 98,259 43.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   AUROBINDO PHARMA  MERCK LTD  NOVARTIS  FULFORD INDIA  ORCHID PHARMA LTD  

Compare FRESENIUS KABI ONCO. With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Rising Dollar after Fed Minutes; F&O Expiry and Top Stocks in Action Today(Pre-Open)

Indian share markets ended largely flat on Thursday following the expiry of derivative contracts for February series. The S&P BSE Sensex ended down by 25 points.

Related Views on News

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. - TORRENT PHARMA COMPARISON

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS